Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

completed267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
terminatednot_applicable

Safety and Efficacy of NF135 CPS Immunization

NCT03813108
completednot_applicable

Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection

NCT02098590
completednot_applicable

Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis

NCT02080026

Clinical Trials (3)

Showing 3 of 3 trials
NCT03813108Not Applicable

Safety and Efficacy of NF135 CPS Immunization

Terminated
NCT02098590Not Applicable

Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection

Completed
NCT02080026Not Applicable

Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis

Completed

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3